GHRP-2rctRCT2004

Activation of somatostatin-receptor subtype-2/-5 suppresses the mass, frequency, and irregularity of growth hormone (GH)-releasing peptide-2-stimulated GH secretion in men.

The Journal of clinical endocrinology and metabolism

confidence

Key findings

SSTR-2/-5 agonism (octreotide) suppressed GHRP-2-stimulated GH burst mass, frequency, and irregularity, but only burst mass with GHRH.

View source on PubMed (PMID 15356066) ↗

Sample size
10 healthy men
Population
Healthy men
Dosing
Octreotide 1 microg/kg sc; GHRH 1 microg/kg iv; GHRP-2 1 microg/kg iv bolus
Duration
Eight randomly ordered separate-day infusion sessions
Route
Subcutaneous (octreotide) and intravenous (peptides)
Blinding
not_reported
Controls
placebo
Drug class
GH secretagogue

Measured endpoints

  • Fasting GH concentration (octreotide vs placebo)Decreasedhormonal
    significanteffect: 0.27 +/- 0.07 to 0.12 +/- 0.02
  • GH secretory burst mass (octreotide vs placebo)Decreasedhormonal
    significanteffect: 2.7 +/- 0.65 to 0.55 +/- 0.11
  • Basal GH secretion (octreotide vs placebo)Decreasedhormonal
    significanteffect: 0.24 +/- 0.043 to 0.11 +/- 0.015
  • GH secretory burst frequency (octreotide vs placebo)No changehormonal
    not_significanteffect: 3.1 +/- 0.5 vs 3.3 +/- 0.21
  • Regularity of GH release (approximate entropy, octreotide vs placebo)No changehormonal
    not_significanteffect: 0.58 +/- 0.048 vs 0.68 +/- 0.064
  • GH secretory burst mass in GHRP-2-stimulated settingDecreasedhormonal
    significanteffect: 28 +/- 3.2 to 18 +/- 2.0
  • GH pulse frequency in GHRP-2-stimulated settingDecreasedhormonal
    significanteffect: 3.3 +/- 0.30 to 2.0 +/- 0.18
  • Irregularity of GH release (approximate entropy) in GHRP-2-stimulated settingDecreasedhormonal
    significanteffect: 0.648 +/- 0.049 to 0.433 +/- 0.047
  • GH secretory burst mass in GHRH/combined GHRH/GHRP-2 settingDecreasedhormonal
    significant
Full abstract

Somatostatin antagonizes the stimulatory actions of GHRH and GH-releasing peptides (GHRPs). However, precisely how the inhibitory susceptibilities of the two secretagogues differ is not clear. One interpretative difficulty is that native somatostatin activates six different receptor subtypes. The present study adopts the complementary strategy of enforcing feedback inhibition via the preferential somatostatin receptor subtype 2 and 5 (SSTR-2/-5) agonist, octreotide. We postulated that putative SSTR-2/-5 agonism would unmask secretagogue-selective interactions in the control of GH secretory burst mass, frequency, and/or regularity. To this end, 10 healthy men each underwent eight randomly ordered, separate-day, fasting morning infusion sessions. Interventions comprised sc administration of octreotide (1 microg/kg), followed by bolus iv injection of saline, GHRH (1 microg/kg), GHRP-2 (1 microg/kg), or both peptides. Compared with placebo, the SSTR-2/-5 agonist reduced fasting GH concentrations from 0.27 +/- 0.07 to 0.12 +/- 0.02 microg/liter (P = 0.020), GH secretory burst mass from 2.7 +/- 0.65 to 0.55 +/- 0.11 microg/liter (P = 0.013), and basal GH secretion from 0.24 +/- 0.043 to 0.11 +/- 0.015 microg/liter.100 min (P = 0.0063). The foregoing outcomes were selective, because octreotide did not alter GH secretory burst frequency (3.1 +/- 0.5 vs. 3.3 +/- 0.21 events/3 h) or the regularity of the GH release process (approximate entropy, 0.58 +/- 0.048 vs. 0.68 +/- 0.064). In the GHRP-2-stimulated setting, presumptive SSTR-2/-5 agonism suppressed all three GH secretory burst masses, from 28 +/- 3.2 to 18 +/- 2.0 (P = 0.045); GH pulse frequency, from 3.3 +/- 0.30 to 2.0 +/- 0.18 (P = 0.0025); and the irregularity (approximate entropy) of GH release, from 0.648 +/- 0.049 to 0.433 +/- 0.047 (P < 0.01). In contrast, in the GHRH and combined GHRH/GHRP-2-stimulated contexts, octreotide decreased only GH secretory burst mass (P = 0.047). In summary, the present data indicate that GH secretory burst mass, frequency, and orderliness are subject to interactive control by at least SSTR-2/-5-dependent feedback and GHRP-dependent feedforward signals.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.